![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Chemical Used in COVID-19 Therapy Development Subject of Allele Patent Lawsuits
Chemical Used in COVID-19 Therapy Development Subject of Allele Patent Lawsuits
October 12, 2020
San Diego-based Allele Biotechnology has filed lawsuits against Regeneron Pharmaceuticals, Pfizer and BioNTech, alleging infringement of its patent for mNeonGreen, a reagent used to develop COVID-19 therapies.
The reagent is a fluorescent protein used in assays to test neutralizing antibody and vaccine candidates. It is “among the brightest monomeric green or yellow fluorescent protein produced to date,” the company claims in its complaint against Regeneron in the U.S. District Court for the Southern District of New York.
In a separate filing in the U.S. District Court for the Southern District of California, Allele accused Pfizer and BioNTech of using the patent commercially without authorization.
“In no way does Allele want to prohibit or slow down development of vaccines or therapeutics discovered using this technology,” explained Allelle’s founder and CEO Jiwu Wang. “Our goal is to have these companies recognize, as many others have before them, the hard work that went into developing this technology and to respect our intellectual property.”
Allele is seeking a jury trial and unspecified monetary damages.
“We are still reviewing the details in the complaint, but we disagree that Regeneron has infringed any valid patent and we will vigorously defend our position against this lawsuit,” a Regeneron spokesperson said.
Pfizer and BioNTech did not respond to request for comment.
Read the full complaint here: www.fdanews.com/10-08-20-alleleregeneroncomplaint.pdf. — Martin Berman-Gorvine
Upcoming Events
-
21Oct